* Biomatrix Inc., of Ridgefield, N.J., has moved from the Nasdaq market (BIOX) to the New York Stock Exchange, where it will trade under the symbol BXM.

* Cytokine Networks Inc., of Seattle, received four Small Business Innovation Research grants from the National Institutes of Health to support the company's cancer drug development. Two grants relate to development of CNI-1493, a small molecule drug designed to block toxicities associated with interleukin-2 and interleukin-12 cancer treatments. The third grant involves research on fibrocyte, an antigen-presenting cell, as a cancer vaccine, and the fourth relates to work on small molecule inhibitors of polyamines, which block immune responses against cancer.

* Immunex Corp., of Seattle, licensed rights from Digital Gene Technologies Inc., of La Jolla, Calif., to a potential therapeutic target molecule in gastrointestinal tract inflammation. Digital identified the molecule by applying its TOGA gene expression technology to Immunex's models of the disease. The collaboration began in December 1997 and is scheduled to be extended for five more years. Immunex said it expects this summer to license other inflammation target molecules identified by Digital.

* Mycogen Corp., of San Diego, and Rhone-Poulenc Group, of Paris, said they signed a letter of intent "to pool plant biotechnology assets" for development of genetically modified plants and seeds. Financial terms were not disclosed. The alliance initially will focus on insect resistant cotton and sugarcane.

No Comments